Although most lung cancers are a result of smoking, approximately 25% of lung cancer cases
worldwide are not attributable to tobacco use, accounting for over 300,000 deaths each …

Lung cancer is the leading cause of cancer death worldwide. The disease is particularly
difficult to detect, and patients often present at an advanced stage. Current treatments have …

BRCA1 and BRCA2 germline mutation–associated breast cancers are known to be deficient
in the process of homologous recombination and often respond favorably to drugs targeting …

To site-specifically incorporate an unnatural amino acid (UAA) into target proteins in Escherichia
coli, we use a suppressor plasmid that provides an engineered suppressor tRNA and …

The adoptive transfer of autologous T cells engineered to express a chimeric antigen receptor
(CAR) has emerged as a promising cancer therapy. Despite impressive clinical efficacy, …

Thyroid goiter is a common condition that is often associated with iodine deficiency. Familial
forms of goiter in areas not known to feature iodine deficiency are much less common. We …

Advanced and metastatic tumors with complex treatment histories drive cancer mortality.
Here we describe the POG570 cohort, a comprehensive whole-genome, transcriptome and …

Purpose: Recent studies have identified mutation signatures of homologous recombination
deficiency (HRD) in over 20% of breast cancers, as well as pancreatic, ovarian, and gastric …

Background Dacomitinib is an irreversible pan-HER tyrosine-kinase inhibitor with preclinical
and clinical evidence of activity in non-small-cell lung cancer. We designed BR.26 to …

Given the success of targeted agents in specific populations it is expected that some degree
of molecular biomarker testing will become standard of care for many, if not all, cancers. To …